A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Inclusion Criteria:

1. Single ascending dose (SAD) part:
2. Male aged 18-55 years (both inclusive) at screening
3. Body mass index between 18.5 kilogram per meter square (kg/m^2) and 27.0 kg/m^2 (both inclusive) at screening
4. Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
5. Multiple ascending dose (MAD) part (MAD QD and MAD QW):
6. Male aged 18-55 years (both inclusive) at screening
7. Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator
8. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
9. Type 2 diabetes (T2D) part:
10. Female of non-childbearing potential or male aged 18-64 years (both inclusive) at screening
11. Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening
12. Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days before screening
13. Treatment naive to antidiabetic drugs or on a stable daily dose(s) of metformin therapy (any metformin formulation any dose) greater than or equal to (>=) 60 days before screening
14. Insulin naive. However, short-term insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes
15. HbA1c in the range of 6.5% (inclusive) and 9.5% (inclusive)

Exclusion Criteria:

1. Single ascending dose (SAD) part:
2. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
3. Glycosylated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 % (48 millimoles per mole (mmol/mol)) at screening
4. Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
5. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
6. Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
7. HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
8. Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
9. Multiple ascending dose (MAD) part (MAD QD and MAD QW):
10. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
11. Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
12. HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
13. Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
14. Type 2 diabetes (T2D) part:
15. Any disorder, except for conditions associated with T2D, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
16. Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus)
17. Current treatment with systemically effective corticosteroids, monoamine oxidase (MAO) inhibitors, systemic non-selective beta-blockers, growth hormone, non-routine vitamins or herbal products
18. Current treatment with selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants